500672 NOVARTIND

Novartis India Share Price

₹1,024.35 +1.45 (0.14%)

21 Nov, 2024 20:01

SIP TrendupStart SIP in NOVARTIND

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume

Investment Returns

  • Over 1 Month -7.72%
  • Over 3 Month -6.71%
  • Over 6 Month -8.45%
  • Over 1 Year + 46.87%
SIP Lightning

Smart Investing Starts Here Start SIP with Novartis India for Steady Growth!

Invest Now

Novartis India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 28.9
  • PEG Ratio
  • 2
  • Market Cap Cr
  • 2,529
  • P/B Ratio
  • 3.4
  • Average True Range
  • 38.52
  • EPS
  • -
  • Dividend Yield
  • 2.4
  • MACD Signal
  • -6.13
  • RSI
  • 39.24
  • MFI
  • 49.35

Novartis India Financials

Novartis India Technicals

EMA & SMA

Current Price
₹1,024.35
+ 1.45 (0.14%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹1,058.20
  • 50 Day
  • ₹1,072.51
  • 100 Day
  • ₹1,074.60
  • 200 Day
  • ₹1,031.83

Resistance and Support

1019.65 Pivot Speed
  • R3 1,095.95
  • R2 1,068.95
  • R1 1,046.65
  • S1 997.35
  • S2 970.35
  • S3 948.05

What's your outlook on Novartis India?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Novartis is a global healthcare company based in Switzerland, specializing in innovative pharmaceuticals and generics. The company focuses on research and development to deliver effective treatments across various therapeutic areas, including oncology, cardiology, and neuroscience, improving patient outcomes worldwide.

Novartis India has an operating revenue of Rs. 345.10 Cr. on a trailing 12-month basis. An annual revenue de-growth of -9% needs improvement, Pre-tax margin of 37% is great, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It is currently FORMING a base in its weekly chart and is trading around 18% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 28 which is a POOR score indicating inconsistency in earnings, a RS Rating of 49 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novartis India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-05-10 Audited Results & Final Dividend
2024-01-25 Quarterly Results
2023-10-27 Quarterly Results
2023-07-26 Quarterly Results

Novartis India F&O

Novartis India Shareholding Pattern

70.68%
0%
0.51%
0.19%
0.01%
23.05%
5.56%

About Novartis India

  • NSE Symbol
  • NOVARTIND
  • BSE Symbol
  • 500672
  • ISIN
  • INE234A01025

Similar Stocks to Novartis India

Novartis India FAQs

Novartis India share price is ₹1,024 As on 21 November, 2024 | 19:47

The Market Cap of Novartis India is ₹2529.2 Cr As on 21 November, 2024 | 19:47

The P/E ratio of Novartis India is 28.9 As on 21 November, 2024 | 19:47

The PB ratio of Novartis India is 3.4 As on 21 November, 2024 | 19:47

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23